

Maria Grazia Daidone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4686991/publications.pdf>

Version: 2024-02-01

236
papers

16,194
citations

23567
58
h-index

18130
120
g-index

241
all docs

241
docs citations

241
times ranked

24380
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 78.	8.6	15
2	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	3.0	2
3	What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. <i>Cancer Medicine</i> , 2022, 11, 332-339.	2.8	6
4	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. <i>Vaccines</i> , 2022, 10, 734.	4.4	0
5	SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region. <i>Cancers</i> , 2021, 13, 1035.	3.7	2
6	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1409.	3.7	9
7	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	3.7	26
8	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	7.0	8
9	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 146, 3495-3503.	5.1	17
10	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. <i>Cells</i> , 2020, 9, 2231.	4.1	8
11	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCS-Istituto Nazionale dei Tumori di Milano. <i>Tumori</i> , 2020, 106, 193-202.	1.1	32
12	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1475.	4.1	25
13	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	4.1	33
14	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. <i>Cancers</i> , 2019, 11, 1152.	3.7	33
15	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	2.8	11
16	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. <i>Cells</i> , 2019, 8, 683.	4.1	21
17	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	3.7	18
18	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	7.0	42

#	ARTICLE	IF	CITATIONS
19	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.7	16
20	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0
21	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. <i>Breast</i> , 2018, 39, 46-52.	2.2	11
22	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 196.	4.1	0
23	Biobanks and scientists: supply and demand. <i>Journal of Translational Medicine</i> , 2018, 16, 136.	4.4	10
24	Workflow for Circulating miRNA Identification and Development in Cancer Research: Methodological Considerations. , 2018, , 103-117.		1
25	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. <i>Seminars in Cancer Biology</i> , 2017, 44, 106-116.	9.6	47
26	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2575-2583.	7.0	16
27	Polyurethane foam scaffold as in vitro model for breast cancer bone metastasis. <i>Acta Biomaterialia</i> , 2017, 63, 306-316.	8.3	58
28	Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer. <i>Molecular Oncology</i> , 2017, 11, 1399-1412.	4.6	6
29	A trans-platinum(II) complex induces apoptosis in cancer stem cells of breast cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 269-276.	3.0	21
30	Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors. <i>Frontiers in Pharmacology</i> , 2017, 8, 226.	3.5	5
31	Metabolic Footprints and Molecular Subtypes in Breast Cancer. <i>Disease Markers</i> , 2017, 2017, 1-19.	1.3	52
32	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. <i>Disease Markers</i> , 2017, 2017, 1-11.	1.3	13
33	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 83-103.	1.6	10
34	Involvement of AF1q/MLLT11 in the progression of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 23246-23264.	1.8	11
35	Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 395-403.	0.4	13
36	Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer. <i>Microarrays (Basel)</i> , 2016, 10, 1-14.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Water-soluble derivatives of 4-(4-hydroxyphenyl) retinamide: synthesis and biological activity. <i>Chemical Biology and Drug Design</i> , 2016, 88, 608-614.	3.2	2
38	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. <i>Breast</i> , 2016, 27, 187-188.	2.2	1
39	Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues. <i>Biopreservation and Biobanking</i> , 2016, 14, 480-490.	1.0	10
40	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345.	7.0	58
41	Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	5.3	37
42	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. <i>Oncotarget</i> , 2016, 7, 58903-58914.	1.8	15
43	In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. <i>Oncotarget</i> , 2016, 7, 976-994.	1.8	10
44	Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. <i>Cancer Medicine</i> , 2015, 4, 1016-1030.	2.8	31
45	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. <i>BMC Bioinformatics</i> , 2015, 16, 388.	2.6	16
46	A Breast Cancer Clinical Registry in An Italian Comprehensive Cancer Center: An Instrument for Descriptive, Clinical, and Experimental Research. <i>Tumori</i> , 2015, 101, 440-446.	1.1	10
47	Lack of Activation of Telomere Maintenance Mechanisms in Human Adipose Stromal Cells Derived from Fatty Portion of Lipoaspirates. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 114e-123e.	1.4	9
48	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	1.8	26
49	Challenges in Using Circulating miRNAs as Cancer Biomarkers. <i>BioMed Research International</i> , 2015, 2015, 1-10.	1.9	202
50	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. <i>British Journal of Cancer</i> , 2015, 113, 290-298.	6.4	40
51	p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. <i>Breast</i> , 2015, 24, 294-297.	2.2	24
52	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
53	Optimizing sharing of hospital biobank samples. <i>Science Translational Medicine</i> , 2015, 7, 297fs31.	12.4	13
54	Circulating Biomarkers for Prediction of Treatment Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 60-63.	2.1	31

#	ARTICLE	IF	CITATIONS
55	Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. <i>Seminars in Cancer Biology</i> , 2015, 35, 3-10.	9.6	120
56	YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. <i>International Journal of Cancer</i> , 2015, 136, 299-309.	5.1	29
57	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 278-289.	3.2	19
58	Implications of stemness-related signaling pathways in breast cancer response to therapy. <i>Seminars in Cancer Biology</i> , 2015, 31, 43-51.	9.6	51
59	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0123194.	2.5	11
60	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. <i>Oncotarget</i> , 2015, 6, 2315-2330.	1.8	43
61	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015, 6, 9627-9642.	1.8	103
62	Association between CASP8 652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. <i>PLoS ONE</i> , 2014, 9, e85538.	2.5	8
63	Cell cycle dependent oscillatory expression of estrogen receptor- α links Pol II elongation to neoplastic transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9561-9566.	7.1	13
64	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	6.4	16
65	A lipemia-independent NanoDrop [®] -based score to identify hemolysis in plasma and serum samples. <i>Bioanalysis</i> , 2014, 6, 1215-1226.	1.5	47
66	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β 2 (TGF β 2) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	2.6	50
67	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. <i>Annals of Oncology</i> , 2014, 25, 352-357.	1.2	53
68	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014, 11, 237-249.	3.0	9
69	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	4.6	39
70	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. <i>PLoS ONE</i> , 2014, 9, e86511.	2.5	10
71	miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e87039.	2.5	59
72	Feasibility of circulating miRNA microarray analysis from archival plasma samples. <i>Analytical Biochemistry</i> , 2013, 437, 123-125.	2.4	23

#	ARTICLE	IF	CITATIONS
73	MicroRNA Detection in Plasma Samples. Journal of Molecular Diagnostics, 2013, 15, 138-139.	2.8	6
74	A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical Reviews in Oncology/Hematology, 2013, 88, 187-197.	4.4	106
75	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells. Angiogenesis, 2013, 16, 707-722.	7.2	5
76	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	2.6	109
77	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. International Journal of Biological Markers, 2013, 28, 24-31.	1.8	0
78	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	2.5	44
79	Measuring MicroRNA Expression Levels in Oncology: from Samples to Data Analysis. Critical Reviews in Oncogenesis, 2013, 18, 273-287.	0.4	21
80	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology, 2013, 31, 1014-1014.	1.6	2
81	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy, 2012, 8, 1185-1196.	9.1	51
82	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro-Oncology, 2012, 14, 736-744.	1.2	21
83	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. European Journal of Cancer, Supplement, 2012, 10, 120-127.	2.2	3
84	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncology, The, 2012, 13, 810-816.	10.7	130
85	AF1q: A Novel Mediator of Basal and 4-HPR-Induced Apoptosis in Ovarian Cancer Cells. PLoS ONE, 2012, 7, e39968.	2.5	19
86	Comparison of Microarray Platforms for Measuring Differential MicroRNA Expression in Paired Normal/Cancer Colon Tissues. PLoS ONE, 2012, 7, e45105.	2.5	52
87	Introduction to Cancer Biobanking: Why, Where, How?. Biopreservation and Biobanking, 2011, 9, 139-140.	1.0	2
88	The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell, 2011, 147, 759-772.	28.9	1,115
89	Novel Immunofluorescence Protocol for Multimarker Assessment of Putative Disseminating Breast Cancer Stem Cells. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 33-40.	1.2	39
90	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. Annals of Surgical Oncology, 2011, 18, 125-133.	1.5	141

#	ARTICLE	IF	CITATIONS
91	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 601-610.	2.5	88
92	Telomere maintenance in wilms tumors: First evidence for the presence of alternative lengthening of telomeres mechanism. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 823-829.	2.8	15
93	Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer. <i>Biopreservation and Biobanking</i> , 2011, 9, 181-186.	1.0	9
94	Concluding Remarks: “Biobanking for Cancer Research: Rules and Roles,” November 2010, Bari, Italy. <i>Biopreservation and Biobanking</i> , 2011, 9, 195-196.	1.0	1
95	Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 55-59.	2.1	3
96	Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies. <i>Cancers</i> , 2011, 3, 1405-1425.	3.7	9
97	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	2.1	61
98	Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. <i>BMC Cancer</i> , 2010, 10, 254.	2.6	30
99	Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1877-1886.	0.7	77
100	miR-21: an oncomir on strike in prostate cancer. <i>Molecular Cancer</i> , 2010, 9, 12.	19.2	189
101	Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. <i>Cancer Letters</i> , 2010, 296, 206-215.	7.2	13
102	A MicroRNA Targeting Dicer for Metastasis Control. <i>Cell</i> , 2010, 141, 1195-1207.	28.9	619
103	Comprehensive cancer control-research & development: knowing what we do and doing what we know. <i>Tumori</i> , 2009, 95, 610-622.	1.1	7
104	Report of the EORTC Laboratory Research Division (LDR) Meeting. <i>Breast Care</i> , 2009, 4, 273-274.	1.4	1
105	Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. <i>British Journal of Cancer</i> , 2009, 100, 739-746.	6.4	47
106	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase C μ . <i>Cancer Research</i> , 2009, 69, 2287-2295.	0.9	334
107	Impact of biospecimens handling on biomarker research in breast cancer. <i>BMC Cancer</i> , 2009, 9, 409.	2.6	81
108	A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. <i>Oncogene</i> , 2009, 28, 3765-3774.	5.9	64

#	ARTICLE	IF	CITATIONS
109	ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. <i>Journal of Pathology</i> , 2008, 214, 410-414.	4.5	13
110	Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 389-390.	2.5	3
111	<i>PIK3CA</i> cancer mutations display gender and tissue specificity patterns. <i>Human Mutation</i> , 2008, 29, 284-288.	2.5	120
112	Breast cancer metastases are molecularly distinct from their primary tumors. <i>Oncogene</i> , 2008, 27, 2148-2158.	5.9	116
113	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , 2008, 9, 239.	2.8	300
114	High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. <i>British Journal of Cancer</i> , 2008, 98, 1467-1474.	6.4	25
115	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
116	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 439-449.	3.1	16
117	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. <i>Clinical Cancer Research</i> , 2008, 14, 4134-4140.	7.0	61
118	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. , 2008, , 15-32.		0
119	Human Bone Marrow-derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term <i>In vitro</i> Culture and Do Not Exhibit Telomere Maintenance Mechanisms. <i>Cancer Research</i> , 2007, 67, 9142-9149.	0.9	649
120	Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. <i>Cell Proliferation</i> , 2007, 40, 905-920.	5.3	24
121	Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. <i>Biochemical Pharmacology</i> , 2007, 73, 773-781.	4.4	40
122	Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. <i>Biochemical Pharmacology</i> , 2007, 73, 1703-1714.	4.4	45
123	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. <i>Analytical Cellular Pathology</i> , 2007, 29, 453-466.	1.4	35
124	Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 179-186.	4.1	73
125	Small-Molecule Targeting of Heat Shock Protein 90 Chaperone Function: A Rational Identification of a New Anticancer Lead. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7721-7730.	6.4	88
126	Breast cancer stem cells: An overview. <i>European Journal of Cancer</i> , 2006, 42, 1219-1224.	2.8	126

#	ARTICLE	IF	CITATIONS
127	A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. <i>Leukemia</i> , 2006, 20, 785-792.	7.2	19
128	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. <i>Cancer Research</i> , 2006, 66, 8918-8924.	0.9	115
129	A Randomized Trial Comparing Axillary Dissection to No Axillary Dissection in Older Patients With T1N0 Breast Cancer. <i>Annals of Surgery</i> , 2005, 242, 1-6.	4.2	181
130	Rational design of shepherdin, a novel anticancer agent. <i>Cancer Cell</i> , 2005, 7, 457-468.	16.8	311
131	Survivin as a target for new anticancer interventions. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 360-372.	3.6	227
132	RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1852-1853.	6.3	2
133	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1851-1852.	6.3	10
134	Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. <i>Journal of the National Cancer Institute</i> , 2005, 97, 927-930.	6.3	110
135	Reproducibility of a Semiquantitative Measurement of Circulating DNA in Plasma From Neoplastic Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 3163-3164.	1.6	26
136	Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres. <i>Clinical Cancer Research</i> , 2005, 11, 2832-2839.	7.0	33
137	30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. <i>BMJ: British Medical Journal</i> , 2005, 330, 217.	2.3	224
138	Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. <i>Cancer Research</i> , 2005, 65, 5506-5511.	0.9	1,650
139	Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. <i>European Journal of Cancer</i> , 2005, 41, 624-634.	2.8	80
140	Prospective evaluation of estrogen receptor- β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. <i>Endocrine-Related Cancer</i> , 2004, 11, 761-770.	3.1	25
141	Different Genetic Features Associated with Colon and Rectal Carcinogenesis. <i>Clinical Cancer Research</i> , 2004, 10, 4015-4021.	7.0	191
142	Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. <i>Carcinogenesis</i> , 2004, 25, 1129-1136.	2.8	57
143	Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. <i>Oncogene</i> , 2004, 23, 386-394.	5.9	92
144	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. <i>Oncogene</i> , 2004, 23, 8171-8183.	5.9	75

#	ARTICLE	IF	CITATIONS
145	Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. <i>Investigational New Drugs</i> , 2004, 22, 207-217.	2.6	37
146	Biomolecular features of clinical relevance in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S3-S14.	6.4	13
147	Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 76-82.	5.4	32
148	Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls. <i>European Journal of Cancer</i> , 2004, 40, 2613-2622.	2.8	15
149	Biomolecular prognostic factors in breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2004, 16, 49-55.	2.0	50
150	Selective modulation of ER- α by estradiol and xenoestrogens in human breast cancer cell lines. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 567-576.	5.4	25
151	Primary breast cancer in elderly women: biological profile and relation with clinical outcome. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 313-325.	4.4	119
152	Radiosensitization of Human Melanoma Cells by Ribozyme-Mediated Inhibition of Survivin Expression. <i>Journal of Investigative Dermatology</i> , 2003, 120, 648-654.	0.7	90
153	Ribozyme-mediated inhibition of PKC ζ sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. <i>Prostate</i> , 2003, 54, 133-143.	2.3	24
154	Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. <i>Journal of Pathology</i> , 2003, 201, 127-133.	4.5	29
155	Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. <i>British Journal of Cancer</i> , 2003, 89, 268-270.	6.4	18
156	Severe hemolytic anemia and skin reaction in a patient treated with imatinib. <i>Annals of Oncology</i> , 2003, 14, 962.	1.2	13
157	Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2003, 95, 629-630.	6.3	11
158	Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. <i>Annals of Oncology</i> , 2003, 14, 1484-1493.	1.2	26
159	Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. <i>Carcinogenesis</i> , 2003, 24, 851-859.	2.8	43
160	Expression of Phosphatidylethanolamine N-Methyltransferase in Human Hepatocellular Carcinomas. <i>Oncology</i> , 2003, 65, 152-158.	1.9	34
161	Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. <i>Cancer Research</i> , 2003, 63, 3490-4.	0.9	55
162	Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. <i>Carcinogenesis</i> , 2002, 23, 735-740.	2.8	55

#	ARTICLE	IF	CITATIONS
163	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3752-3753.	1.6	20
164	Coexpression of survivin and TERT in soft-tissue sarcoma. <i>Lancet, The</i> , 2002, 360, 877.	13.7	4
165	Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. <i>Drug Resistance Updates</i> , 2002, 5, 65-72.	14.4	177
166	Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells. <i>European Journal of Cancer</i> , 2002, 38, 1792-1801.	2.8	39
167	Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 1406-1412.	5.4	246
168	Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. <i>Journal of Pathology</i> , 2002, 198, 37-46.	4.5	32
169	Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. <i>British Journal of Cancer</i> , 2002, 87, 1105-1111.	6.4	57
170	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. <i>Journal of Clinical Investigation</i> , 2002, 109, 285-286.	8.2	73
171	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. <i>Journal of Clinical Investigation</i> , 2002, 109, 285-286.	8.2	51
172	Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions. <i>British Journal of Cancer</i> , 2001, 84, 1387-1390.	6.4	27
173	The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52, 197-202.	4.3	14
174	Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. <i>European Journal of Cancer</i> , 2001, 37, 649-659.	2.8	27
175	Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. <i>European Journal of Cancer</i> , 2001, 37, 1953-1962.	2.8	38
176	Cell proliferation markers in human solid tumors: Assessing their impact in clinical oncology. <i>Methods in Cell Biology</i> , 2001, 64, 359-384.	1.1	8
177	Possible Regulation of Telomerase Activity by Transcription and Alternative Splicing of Telomerase Reverse Transcriptase in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2001, 116, 867-873.	0.7	37
178	Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. <i>International Journal of Cancer</i> , 2001, 91, 654-657.	5.1	43
179	Effects of liposome-entrapped annexin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis. <i>Journal of Cellular Biochemistry</i> , 2001, 81, 9-22.	2.6	3
180	Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2001, 84, 651-658.	6.4	30

#	ARTICLE	IF	CITATIONS
181	Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. <i>Oncogene</i> , 2001, 20, 980-988.	5.9	73
182	Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. <i>British Journal of Cancer</i> , 2001, 85, 795-797.	6.4	28
183	Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. <i>International Journal of Cancer</i> , 2000, 87, 405-411.	5.1	23
184	Inhibition of Telomerase Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 259-267.	0.7	68
185	Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. <i>Cell Proliferation</i> , 2000, 33, 139-146.	5.3	66
186	Time-Dependent Relevance of Steroid Receptors in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2702-2709.	1.6	47
187	Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. <i>European Journal of Cancer</i> , 2000, 36, 2137-2145.	2.8	28
188	Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. <i>FEBS Letters</i> , 2000, 473, 241-248.	2.8	82
189	Clinical studies of Bcl-2 and treatment benefit in breast cancer patients.. <i>Endocrine-Related Cancer</i> , 1999, 6, 61-68.	3.1	69
190	Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. <i>British Journal of Cancer</i> , 1999, 81, 252-260.	6.4	19
191	Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. <i>International Journal of Cancer</i> , 1999, 81, 411-416.	5.1	98
192	Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. <i>International Journal of Cancer</i> , 1999, 84, 580-586.	5.1	49
193	Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. <i>International Journal of Cancer</i> , 1999, 81, 411-416.	5.1	1
194	Effect of menstrual phase on cell proliferative rate of breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 93-94.	2.5	5
195	The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. , 1998, 82, 159-167.		34
196	Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. , 1998, 79, 619-623.		28
197	Association between [18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1429-1434.	6.4	161
198	Telomerase Activity in Benign and Malignant Breast Lesions: a Pilot Prospective Study on Fine-Needle Aspirates. <i>Journal of the National Cancer Institute</i> , 1998, 90, 537-539.	6.3	25

#	ARTICLE	IF	CITATIONS
199	Tissue Polypeptide Antigen as a Putative Indicator of Apoptosis. Clinical Chemistry, 1998, 44, 2002-2003.	3.2	6
200	P53 Accumulation in Primary Breast Cancer: A Comparison between Immunohistochemistry and a Novel Luminometric Immunoassay. Tumor Biology, 1998, 19, 12-18.	1.8	5
201	Fixation Time and Microwave Oven Irradiation Affect Immunocytochemical p53 Detection in Formalin-Fixed Paraffin Sections. Applied Immunohistochemistry & Molecular Morphology, 1998, 6, 140-144.	2.0	4
202	Expression of p53, Glutathione S -Transferase- α , and Bcl-2 Proteins and Benefit From Adjuvant Radiotherapy in Breast Cancer. Journal of the National Cancer Institute, 1997, 89, 639-645.	6.3	91
203	Cell proliferation in 3,800 node-negative breast cancers: Concistency over time of biological and clinical information provided by 3H-Thymidine labelling index. International Journal of Cancer, 1997, 74, 122-127.	5.1	61
204	int-2 Oncogene amplification and prognosis in node-negative breast carcinoma. , 1997, 74, 620-624.		16
205	p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. European Journal of Cancer, 1996, 32, 1388-1393.	2.8	9
206	Changes in biological markers after primary chemotherapy for breast cancers. International Journal of Cancer, 1995, 61, 301-305.	5.1	44
207	Contribution of ploidy and cell kinetics from fine-needle aspirates for the diagnosis of breast lesions: Study of 606 consecutive cases. Cytometry, 1995, 22, 177-180.	1.8	3
208	Immunohistochemical Detection of p53 in Clinical Breast Cancers: a Look at Methodologic Approaches. Journal of the National Cancer Institute, 1995, 87, 1020-1020.	6.3	22
209	Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. European Journal of Cancer, 1994, 30, 1002-1007.	2.8	63
210	The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1994, 86, 499-504.	6.3	423
211	Combined analysis of ploidy and cell kinetics on fine-needle aspirates from breast tumors. Cancer, 1993, 71, 2522-2527.	4.1	7
212	Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Research and Treatment, 1993, 26, 7-13.	2.5	13
213	p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1993, 85, 965-970.	6.3	226
214	Clusterin: A potential target for improving response to antiestrogens. International Journal of Oncology, 1992, 33, 791.	3.3	4
215	Potentials of cell kinetics in the management of patients with ovarian cancers. European Journal of Cancer, 1992, 28, 386-390.	2.8	12
216	Biological characterisation of primary and metachronous lesions in breast cancer patients. European Journal of Cancer, 1992, 28, 2006-2010.	2.8	7

#	ARTICLE	IF	CITATIONS
217	Changes in cell kinetics induced by primary chemotherapy in breast cancer. International Journal of Cancer, 1991, 47, 380-383.	5.1	25
218	Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. International Journal of Cancer, 1991, 48, 529-532.	5.1	90
219	Comparing core needle to surgical biopsies in breast cancer for cell kinetic and ploidy studies. Breast Cancer Research and Treatment, 1991, 19, 33-37.	2.5	3
220	3H-Thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients. Breast Cancer Research and Treatment, 1991, 20, 19-24.	2.5	17
221	Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index. Cell Proliferation, 1990, 23, 401-408.	5.3	7
222	Cell Kinetics of Solid Tumors with Time and Its Clinical Implication. Tumori, 1989, 75, 367-372.	1.1	25
223	Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. International Journal of Cell Cloning, 1989, 7, 385-394.	1.6	17
224	Cell kinetics as a prognostic indicator in node-negative breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 1165-1171.	0.7	88
225	Cell Kinetics: A prognostic marker in epithelial ovarian cancer. Gynecologic Oncology, 1989, 35, 15-19.	1.4	23
226	Drug Sensitivity of Different Tumor Lesions from the Same Patient Evaluated by a Short-Term Assay. Tumori, 1988, 74, 137-144.	1.1	3
227	Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. Investigational New Drugs, 1987, 5, 245-50.	2.6	5
228	Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Research and Treatment, 1986, 7, 161-169.	2.5	138
229	Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer, 1985, 56, 450-456.	4.1	24
230	Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer, 1985, 56, 1982-1987.	4.1	207
231	In Vitro Activity of Alkylating Agents on Human Tumors as Measured by a Short-term Antimetabolic Assay. Tumori, 1985, 71, 555-561.	1.1	5
232	Cell kinetics and in Vitro chemosensitivity as a tool for improved management of patients. European Journal of Cancer & Clinical Oncology, 1985, 21, 371-378.	0.7	19
233	Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Research and Treatment, 1981, 1, 253-262.	2.5	43
234	Estimation of differential in vitro sensitivity of non-hodgkin lymphomas to anticancer drugs. European Journal of Cancer, 1981, 17, 217-226.	0.9	32

#	ARTICLE	IF	CITATIONS
235	Short-term tissue culture of human breast cancer. Presence of estrogen receptors and 17 β -estradiol stimulation of RNA synthesis. Cancer, 1979, 43, 2365-2369.	4.1	9
236	Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer, 1979, 44, 665-670.	4.1	126